The finding that BRAF V600E alteration is a biomarker negatively associated with survival is contradictory to historical cohorts.8,15 We propose this is due, at least in part, to the poor response of BRAF V600E brain metastases to ICI, which has only recently become a commonly used systemic regimen for melanoma brain metastases. This evidence concerns the gene BRAF and melanoma.